FDASIA Committee Background David W. Bates MD, MSc, Chair 1.

Slides:



Advertisements
Similar presentations
Elizabeth Mansfield, PhD OIVD Public meeting July 19, 2010
Advertisements

Drug Information for Consumers and Healthcare Professionals Food and Drug Law Institute Annual Meeting Alan Goldhammer, PhD Associate VP Regulatory Affairs.
Legal Work Group Developing a Uniform EHR/HIE Patient Consent Form.
Medication Management
Bangor Beacon Community Technology Overview Presented to Maine Health IT Steering Committee July 8,
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
Sep 13 Fall 05 Electronic Medical Records (EMR) Computerized Patient Record (CPR) Electronic Health Record (EHR)
Patient Navigation Breast Health Patient Navigator Program.
INTRO TO MEDICAL INFORMATICS: TUTORIAL
Western Australian Emergency Medicine Research Online WAEMRO Dis-integrating healthcare information systems Professor Peter Sprivulis MBBS PhD FACEM FACHI.
Assignment Four Underwriting. Definitions Underwriting – The process of selecting policyholders by recognizing and evaluation hazards, establishing prices.
Introduction to Regulation
Lecture 6 Personal Health Record (Chapter 16)
HITSP – enabling healthcare interoperability 1 enabling healthcare interoperability 1 Standards Harmonization HITSP’s efforts to address HIT-related provisions.
Medical Devices Approval Process
Quality Assurance: Manufacturer & Clinical Aspects  Alan Cohen, M.S. DABR  Paul Naine, MSc. MIPEM  Jim Schewe, PhD, DABMP Accuray Incorporated Elekta.
Behavioral Health Services for Injured or Ill workers – Collaborative Care Analysis and Recommendations January 22, 2015.
Theresa Tsosie-Robledo MS RN-BC February 15, 2012
RENI PRIMA GUSTY, SK.p,M.Kes
Chapter 2 Electronic Health Records
Research & Innovation Horizon societal challenge 1 Open Info Day Funding Opportunities for SMEs Horizon 2020 "Health, demographic change and wellbeing"
Unit 6b: Clinical Decision Support Systems that Help Improve Quality Decision Support for Quality Improvement This material was developed by Johns Hopkins.
Patient Centered Medical Home What it means for Duffy Health Center Board Presentation September 10 th 2012.
FDASIA REGULATIONS SUBCOMMITTEE May 22, Agenda 4:00 p.m.Call to Order – MacKenzie Robertson Office of the National Coordinator for Health Information.
Decision Support for Quality Improvement
Technology Council of Maryland Health IT Forum “Big Data” and the Real World.
FDASIA Health IT Report Jodi G. Daniel, JD, MPH Director, Office of Policy and Planning, ONC May 6, 2014.
Eureka Pre-Clinical Investigation Animal toxicology Animal pharmacokinetics/ pharmacodynamics Clinical Investigation Phase I Safety and pharmacology Phase.
Stakeholders In Clinical Research Government and Regulatory Bodies Professor Phil Warner.
Patient Safety and Medical Devices Sonia Swayze, RN, MA, C and Suzanne Rich, RN, MA, CT.
FDASIA Taxonomy Subgroup HIT Policy Committee FDASIA Workgroup On Site Meeting 30 May 2013.
Community Paramedic. Benchmark 101 We need a description of the epidemiology of the medical conditions targeted by the community paramedicine program.
Implications for the Use of Tissue in Research P. Pearl O’Rourke, MD Partners HealthCare Boston, MA.
Alliance of Chicago Community Health Services EHRS-enabled PBRN of safety net health centers Fred Rachman, MD Erin Kaleba, MPH.
Interoperability Showcase In collaboration with IHE Use Case 3 Care Theme: Leveraging National Healthcare Registries in Care Delivery Biosurveillance Monitoring.
SALDA Presentation to the Honourable Portfolio Committee on Health National Health Act Amendment Bill B March 2012.
© 2011 Underwriters Laboratories Inc. All rights reserved. This document may not be reproduced or distributed without authorization. ASSET Safety Management.
Standard 4: Medication Safety Advice Centre Network Meeting Margaret Duguid Pharmaceutical Advisor February 2013.
Applying Science to Transform Lives TREATMENT RESEARCH INSTITUTE TRI science addiction Mady Chalk, Ph.D Treatment Research Institute CADPAAC Conference.
FDA & MOBILE/IT APPLICATIONS Drew Bennett Sr. Technical Licensing Specialist Office of Technology Transfer.
+ National and Institutional Guidelines on Conflict of Interest in Physician-Industry Relationships.
Clinical Decision Support Systems Paula Coe MSN, RN, NEA-BC NUR 705 Informatics and Technology for Improving Outcomes in Advanced Practice Nursing Dr.
CDRH INITIATIVES FOR AGING IN PLACE NIH Aging in Place Workshop September 10-11, 2014 Presented by Mary Brady, MSN, RN Senior Policy Advisor Center for.
Using Medicines Safely (2:50) Click here to launch video Click here to download print activity.
FDASIA Taxonomy Subgroup HIT Policy Committee FDASIA Workgroup Virtual Meeting 14 June 2013.
Medication Error Reduction Principles in Practice Copyright © – Academy of Managed Care Pharmacy (AMCP)Slide 1.
Accountable Care Organizations: What is the role of the pathologist? What are the public policy implications?
Investigational Devices and Humanitarian Use Devices June 2007.
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
Questions to Committee about Potential Cancer Risk with Use of Topical Immunosuppressants (Calcineurin Inhibitors) Question 1: Messages about Risk A. Based.
1 PRIORITY MEDICINES FOR EUROPE AND THE WORLD Barriers to Pharmaceutical Innovation Richard Laing EDM/PAR WHO.
ICD-10 Operational and Revenue Cycle Impacts Wendy Haas, MBA, RN Dell Services Healthcare Consulting.
Steps for the Integration of Traditional Medicine in the National Health Care Delivery System 18 TH ICASA Special Session on Traditional Medicine 1 st.
27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.
1 Developed by: U-MIC To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the.
Health Informatics Awareness Planned DayTopicPlanned Time Day 1 22/7/ Course introduction & pre course survey 2.Pre evaluation test 3.Introduction.
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
All Hands Electronic Information Integrity Call White Paper An Introduction to the Current State of EMR – et.al. R. L. Chamberlain, Ph.D.
Regulatory Updates Health Sciences Authority Singapore
Improvement Activities
The Working Group on Medical Measurements The 23rd Forum Meeting
HL7 International January Working Group Meeting Health Care Device WG
Software & Apps - to be a medical device or not
Using Medicines Safely (2:50)
Which Projects Do – and do Not – Require IRB Review?
CS581 Electronic Health Records Term Project
Which Projects Do – and do Not – Require IRB Review?
Tobey Clark, Director*, Burlington USA
Electronic Communication and the Internet
Regulatory Perspective of the Use of EHRs in RCTs
Presentation transcript:

FDASIA Committee Background David W. Bates MD, MSc, Chair 1

Defining Characteristics 1.User type 2.Phases of product lifecycle 3.Developer/ ‘Manufacturer’ Type 4.Distribution model 5.Conditions of use 6.Intended use 7.Product categories 8.Miscellaneous

User Types Health Care Providers – institutional and individual Clinical Researchers using on human subjects Patients under care by a provider General public user/consumer under own use/health management Out of scopeIn Scope

Product Lifecycle Design phase Testing Implementation- Installation Maintenance & enhancement Availability-Downtime Hazard Recall Retirement Methods and modes of end- user training In Scope Out of Scope

Developer/ ‘Manufacturer’ Types Entity which develops, markets, licenses, or distributes products with commercial interest Entity which develops, advertises or distributes via public channel products intended for general public users, even if no commercial interest Healthcare provider* who develops products de novo for use on patients, even if no direct or indirect commercial interest Healthcare provider* who modifies functionality of previously licensed, ‘finished’ products Individual who develops for personal private use Individual who develops/distributes via private channel to limited individuals without commercial interest In ScopeOut of Scope *institutional or individual provider

Distribution Model Marketed-licensed- distributed-sold in a restricted manner, with credentialing requirements Marketed-licensed- distributed-sold in a restricted manner, without credentialing requirements Made available for download via an unrestricted public channel, with or without credentialing requirements Available under a SaaS model In ScopePotentially Out of Scope

Conditions of Use By prescription, recommendation or under direction of licensed/credentialed healthcare provider Independently by general public consumer/user For management of defined illness or chronic condition For research purposes on human subjects Intended use Foreseeable misuse (e.g. interface lacks forcing functions to preclude double entry) For health maintenance or fitness Non-foreseeable, willful misuse Use clearly beyond labeled intended use In Scope Out of Scope

Products Types - Categories EHRs (installed, SaaS) Hospital Information Systems-of-systems Decision support algorithms Visualization tools for anatomic, tissue images, medical imaging and waveforms Health Information Exchanges Electronic/robotic patient care assistants Claims processing Health benefit eligibility Practice management / Scheduling / Inventory management General purpose communication tools (e.g., , paging) used by health professionals Population management tools Software using historical claims data to predict future utilization/cost of care Cost effectiveness analytic software Diseases severity scoring algorithms Electronic guideline distribution Disease registries In ScopeOut of Scope

Miscellaneous Regulation around Privacy (HIPAA) In ScopeOut of Scope

DECISION TREE APPROACH FOR DETERMINING WHETHER OR NOT AN ENTITY REQUIRES RISK-BASED REGULATION Functionality – Potential for Harm

Diagram Is function of the entity to inform or change decision making about: - initiating - discontinuing - modifying care interventions or personal health management ? Is function of the entity to inform or change decision making about: - initiating - discontinuing - modifying care interventions or personal health management ? Yes NO Out-of-scope … defer to existing regulatory framework In-scope

Diagram 2 Does malfunction, foreseeable misuse have potential to cause patient injury, via: Delay or failure to present clinical data/ information at time of need Presentation of outdated information Patient-data mismatch? Does malfunction, foreseeable misuse have potential to cause patient injury, via: Delay or failure to present clinical data/ information at time of need Presentation of outdated information Patient-data mismatch? YES NO in-scope out-of-scope

Diagram 2 Is the data/information that is managed by system the sole or 1 o source of data at point of care (i.e., no alternate sources of data / info that can be used for confirmation) ? Is the data/information that is managed by system the sole or 1 o source of data at point of care (i.e., no alternate sources of data / info that can be used for confirmation) ? YES NO in-scope out-of-scope

Diagram 2 Through design and intended use, is patient or provider reliant on data/information to initiate or modify prescribed intervention or treatment ? Through design and intended use, is patient or provider reliant on data/information to initiate or modify prescribed intervention or treatment ? YES NO in-scope out-of-scope

Diagram Does product currently meet FDA (Act 21 CFR) definition of Medical Device (including MDDS) ? Does product currently meet FDA (Act 21 CFR) definition of Medical Device (including MDDS) ? NO YES out of scope in-scope

Sample Use Cases A psychologist creates a mood-tracking app and provides it free of cost to her patients – Does not require from risk-based regulation Requires professional oversight to make treatment decisions, distributed in private channel Rehabilitation specialist develops and sells a electronic coaching aid (sensor-embedded exercise band) for monitoring post-stroke range- of-motion exercise performance remotely – In-scope for risk-based regulation – Function is independent of clinician oversight, risk of misuse is high Hospital’s IT services modifies a drug-drug interaction app that overlays the institution’s EMR – In-scope for risk-based regulation Part of the systems lifecycle; recommends treatment decisions

Summary Taxonomy guides the assignment of HIT innovations into two categories: “Requires for Risk-based Regulation” or “Does not require risk-based regulation” HIT innovations described by 8 characteristics Decision tree guides assignment based on function and potential for harm